Tag: ovulation inducing drugs industry analysis

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Current and Projected Market Size of the Ovulation Inducing Drugs Market Through 2034?

The market size of ovulation inducing drugs has seen considerable growth in recent times. The market is forecasted to increase from $4.42 billion in 2024 to $4.7 billion in 2025, at a compound annual growth rate (CAGR) of 6.5%. The historical growth pattern can be associated with the development of clomiphene citrate, the introduction of letrozole, regulatory authorizations and standardization procedures, and the emergence of ovulation prediction kits.

The market size for ovulation inducing drugs is set for considerable expansion in the coming years, predicted to reach $6.11 billion in 2029 with a compound annual growth rate (CAGR) of 6.8%. This growth in the forecast period is largely due to factors such as modifications in lifestyle and postponed childbearing, integration of digital health, increased market outreach, proliferating infertility rates, and specially tailored treatment plans. Among the major trends anticipated during the forecast period are individualized treatment methodologies, progress in reproductive endocrinology, non-intrusive fertility tracking, increased demand for assisted reproductive technologies, and the creation of new drug formulations.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13256&type=smp

What Are the Major Market Drivers Behind the Rising Adoption of Ovulation Inducing Drugs Market?

With the steady rise in the incidence of female infertility, the ovulation-inducing medication market is projected to expand. Female infertility is defined as a biological condition in which a woman is unable to get pregnant or sustain a pregnancy full term despite frequent participation in unprotected sexual activities over an extended time, usually a year or longer. Ovulation-inducing medications are utilized to rectify issues of inconsistent or non-existent ovulation in order to treat women’s infertility. They manipulate hormone pathways involved in ovulation, prompting the ovaries to release mature eggs. The Centers for Disease Control and Prevention, a US government entity, forecasts that out of all women, 10% equivalent to 6.1 million women between the ages of 15 and 44 in the US, will experience difficulties in conceiving in 2022. Moreover, in June 2022, the US medical management firm, CCRM Management Company LLC stated that on an average, 1 in 4 couples worldwide are affected by infertility, with an annual increase of between 5% and 10%. Given these factors, the surge in female infertility significantly contributes to the growth of the ovulation-inducing drug market.

Which Key Market Segments Comprise the Ovulation Inducing Drugs Market and Drive Its Revenue Growth?

The ovulation inducing drugs market covered in this report is segmented –

1) By Drug Class: Hormones, Therapeutics Drugs

2) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration

3) By End-User: Hospital, Homecare, Specialty Clinics, Other End-Users

Subsegments:

1) By Hormones: Gonadotropins, Clomiphene Citrate, Aromatase Inhibitors

2) By Therapeutic Drugs: Metformin, Letrozole, Bromocriptine

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=13256&type=smp

Which Areas Are Leading Regions in the Ovulation Inducing Drugs Market Expansion Across the Globe?

North America was the largest region in the ovulation-inducing drugs market in 2024. The regions covered in the ovulation inducing drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

What Are the Strategic Trends Steering theOvulation Inducing Drugs Market Direction?

Prominent players in the ovulation-inducing drugs sector are advancing in the creation of ingenious medications such as Cetrorelix acetate and securing the necessary permissions for its use in treating women engaged in controlled ovarian stimulation. Cetrorelix acetate for injection or cetrorelix functions as a gonadotropin-releasing hormone (GnRH) antagonist, safeguarding against premature ovulation in women partaking in in vitro fertilization (IVF). An example would be Akorn Operating Company LLC, a pharmaceutical company situated in the US, which obtained FDA approval for a generic version of the cetrorelix acetate for injection, 0.25 mg (Cetrorelix), in August 2022. This is the first AP-rated bioequivalent of the Merck Serono Cetrotide version to be permitted. Cetrorelix acetate, a GnRH antagonist, operates by intercepting the effects of the gonadotropin-releasing hormone (GnRH). GnRH stimulates the dispersion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) from the pituitary gland. Moreover, it’s utilized to hamper premature LH surges in women experiencing controlled ovarian stimulation (COS) and to ensure that all of the eggs get an opportunity to ripen.

View the full report here:

https://www.thebusinessresearchcompany.com/report/ovulation-inducing-drugs-global-market-report

How Is the Ovulation Inducing Drugs Market Conceptually Defined?

Ovulation-inducing drugs refer to medications that are used to stimulate the ovaries and promote the release of mature eggs (ovulation) in women who are experiencing difficulties with their menstrual cycles or are struggling with infertility. These drugs affect the hormonal balance in the body, specifically targeting the hormones involved in the ovulation process.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13256

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

#How Has the Ovulation Inducing Drugs Market Size Changed, over the years?#_x000D_

The market size of ovulation-inducing drugs has seen steadfast growth in the past years. The projection is an increase from $4.42 billion in 2024 to $4.74 billion in 2025, with a compound annual growth rate (CAGR) of 7.3%. The substantial expansion in previous years can be tied to the creation of clomiphene citrate, the introduction of letrozole, regulatory certifications, market standardization, and the development of ovulation predictor kits._x000D_

_x000D_

#How Much Will the Ovulation Inducing Drugs Market Be Worth in 2029?#_x000D_

Anticipated to experience significant expansion in the coming years, the ovulation inducing drugs market is slated to reach $6.12 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 6.6%. This projected growth within the forecasted period can be ascribed to several factors such as evolving lifestyles, postponement of childbearing, incorporation of digital health, market expansion, increasing infertility rates, and tailored treatment plans. Key trends during this time frame are expected to be individualized treatment strategies, progress in reproductive endocrinology, non-intrusive fertility tracking, escalating demand for assisted reproductive technologies, and the creation of innovative drug formulations._x000D_

_x000D_

#Download The Free Sample Report Here:#_x000D_

https://www.thebusinessresearchcompany.com/sample.aspx?id=13256&type=smp_x000D_

_x000D_

#Which is the Largest Company in the Ovulation Inducing Drugs Market?#_x000D_

Major companies operating in the ovulation inducing drugs market report are Pfizer Inc., Johnson And Johnson Pvt Ltd., Merck And Co. Inc., Abbvie Inc., Novartis AG, Bayer AG, Sanofi SA, Abbott Laboratories, Gilead Sciences Inc., Amgen Inc., Teva Pharmaceutical Industries Ltd., Janssen Pharmaceutical Inc., Mylan N.V, Astellas Pharma Inc., Sun Pharmaceuticals Industries Ltd., Aurobindo Pharma Limited, Dr Reddy’s Laboratories Ltd., Intas Pharmaceuticals Limited, Endo International Inc., Ferring Pharmaceuticals Inc., Lupin Limited, LIVZON Pharmaceutical Group Inc., Torrent Pharmaceuticals Ltd., Gedeon Richter PLC, Glenmark Pharmaceuticals Ltd., Fresenius Kabi AG, Zydus Pharmaceuticals (USA) Inc., Serum Institute of India Ltd., EMD Serono Inc., Cipla Inc._x000D_

_x000D_

#What Are the Main Market Drivers in the Ovulation Inducing Drugs Industry?#_x000D_

The escalating rates of female infertility are projected to spur the expansion of the ovulation-inducing drug market. Women’s infertility is a biological anomaly where a woman cannot get pregnant or maintain a pregnancy to full term, even after regular unprotected sexual activities over a considerable length of time, usually around a year or more. Ovulation-inducing drugs, designed to rectify irregular or non-existent ovulation, are employed as a remedy for this form of infertility. These medications stimulate the hormonal pathways involved in ovulation and encourage the ovaries to release fully developed eggs. For example, the Centers for Disease Control and Prevention, a government agency in the United States, forecasted that in 2022, around 6.1 million women aged between 15 and 44 in the US will have difficulties getting pregnant, representing 10% of the total female population. Furthermore, CCRM Management Company LLC, a medical management firm in the US, stated in June 2022 that infertility impacts 1 in 4 couples around the world on average and escalates by 5% to 10% each year. Consequently, the increasing incidence of women’s infertility acts as a catalyst for the growth in the sales of ovulation-inducing drugs. As an additional factor propelling the ovulation-inducing drugs market, there is an increasing number of patients choosing in-vitro fertilization (IVF). IVF is a series of intricate procedures aiding people and couples with fertility issues in achieving pregnancy. The application of ovulation-inducing drugs is a common IVF protocol, aiming to stimulate ovarian function and facilitate the production of multiple eggs for collection. These drugs are incorporated within the IVF treatment to maximize the probability of a successful outcome. For example, it was reported by The Society for Assisted Reproductive Technology, a US-based organization consisting of doctors and laboratory scientists, that in April 2024, there was a significant surge in egg-freezing cycles, rising from 24,560 in the previous year to 29,803 in 2022. Thus, the swelling numbers of patients resorting to IVF feed directly into the growth of the ovulation-inducing drugs market._x000D_

_x000D_

#Request For A Customized Report:#_x000D_

https://www.thebusinessresearchcompany.com/customise?id=13256&type=smp_x000D_

_x000D_

#How Is the Ovulation Inducing Drugs Market Segments Structured?#_x000D_

The ovulation inducing drugs market covered in this report is segmented –_x000D_

_x000D_

1) By Drug Class: Hormones, Therapeutics Drugs_x000D_

2) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration_x000D_

3) By End-User: Hospital, Homecare, Specialty Clinics, Other End-Users_x000D_

_x000D_

Subsegments:_x000D_

1) By Hormones: Gonadotropins, Clomiphene Citrate, Aromatase Inhibitors_x000D_

2) By Therapeutic Drugs: Metformin, Letrozole, Bromocriptine_x000D_

_x000D_

#What Strategic Trends Are Transforming the Ovulation Inducing Drugs Market?#_x000D_

Leading entities in the ovulation-induction medications sector are focusing on the development of groundbreaking drugs like Cetrorelix acetate, driving advancements in treatment for females experiencing controlled ovarian stimulation. Cetrorelix acetate for injection (cetrorelix) specifically acts as a gonadotropin-releasing hormone (GnRH) antagonist, blocking premature ovulation during in-vitro fertilization (IVF) procedures. In August 2022, a significant progression was made when Akorn Operating Company LLC, an American pharmaceutical firm, acquired FDA approval for their generic version of cetrorelix acetate for injection, 0.25mg (Cetrorelix). This is the first bioequivalent to the AP-rated Merck Serono Cetrotide that has received authorization. The major operating principle of Cetrorelix acetate is to act as a GnRH antagonist, thereby inhibiting the effects of GnRH. Notably, GnRH is instrumental in stimulating the pituitary gland to release luteinizing hormone (LH) and follicle-stimulating hormone (FSH). Moreover, Cetrorelix acetate is utilized to suppress premature LH surges among women experiencing controlled ovarian stimulation (COS), providing each egg the opportunity to mature fully._x000D_

_x000D_

#Access The Full Report Here:#_x000D_

https://www.thebusinessresearchcompany.com/report/ovulation-inducing-drugs-global-market-report_x000D_

_x000D_

#Which Global Regions Offer the Highest Growth in the Ovulation Inducing Drugs Market?#_x000D_

North America was the largest region in the ovulation-inducing drugs market in 2024. The regions covered in the ovulation inducing drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa_x000D_

_x000D_

#Purchase The Full Report Today:#_x000D_

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13256_x000D_

_x000D_

#This Report Delivers Insight On: #_x000D_

1. How big is the ovulation inducing drugs market, and how is it changing globally?_x000D_

2. Who are the major companies in the ovulation inducing drugs market, and how are they performing?_x000D_

3. What are the key opportunities and risks in the ovulation inducing drugs market right now?_x000D_

4. Which products or customer segments are growing the most in the ovulation inducing drugs market?_x000D_

5. What factors are helping or slowing down the growth of the ovulation inducing drugs market?_x000D_

_x000D_

#About The Business Research Company:#_x000D_

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game._x000D_

_x000D_

#Get in touch with us:#_x000D_

The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_

Americas +1 310-496-7795_x000D_

Asia +44 2071930708_x000D_

Europe +44 7882 955267_x000D_

Email us at info@tbrc.info_x000D_

_x000D_

#Follow us on:#_x000D_

_x000D_

LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!

Which Major Market Drivers Are Expected to Boost the Growth Potential of the Ovulation Inducing Drugs Market?

The escalating occurrence of fertility issues among women is predicted to fuel the expansion of the ovulation drug market. Women’s infertility is a physiological issue where a woman is unable to get pregnant or maintain her pregnancy to full term, despite regular unprotected sexual activity for over a year. Ovulation drugs are utilized to remedy these fertility issues by addressing inconsistent or non-existent ovulation. They work by interacting with the hormonal systems that control ovulation, causing the ovaries to release mature eggs. For example, the Centers for Disease Control and Prevention, a government agency in the US, predicts that in 2022, 6.1 million women aged between 15 and 44 will have difficulty getting pregnant, which is roughly 10% of all women. Moreover, according to CCRM Management Company LLC, a medical management company in the US, 1 in 4 couples worldwide struggle with infertility, a figure that is increasing by 5% to 10% annually. Hence, the rising occurrence of women’s infertility is accelerating the growth of the ovulation drug market. Growth in the ovulation drug market is also expected as a consequence of increasing patients choosing in vitro fertilization (IVF). IVF is a detailed set of procedures that assist individuals and couples with fertility issues in achieving pregnancy. IVF treatment involves using ovulation drugs to stimulate the ovaries and produce multiple eggs for extraction. The medication is used during IVF to enhance the chances of successful treatment. The Society for Assisted Reproductive Technology, a US organization that includes doctors and lab scientists, reported in April 2024 a significant increase in egg-freezing cycles – from 24,560 the previous year to 29,803 in 2022. Thus, the mounting number of patients opting for IVF is stimulating the growth of the ovulation drug market.

Get Your Free Sample Report Now – Explore Exclusive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13256&type=smp

#What is the Growth Potential of the Ovulation Inducing Drugs Market, and How Will It Perform by 2034?

The market size for drugs that induce ovulation has seen noteworthy expansion in the past few years. Its growth is expected to escalate from $4.42 billion in 2024 to $4.74 billion in 2025, giving a compound annual growth rate (CAGR) of 7.3%. The surge during the historic period can be credited to progression in clomiphene citrate, the launch of letrozole, regulatory consents, standardizations, and the arrival of ovulation prediction kits.

The market for ovulation stimulating medications is anticipated to experience robust growth in the upcoming years, reaching a valuation of $6.12 billion by 2029 with a 6.6% compound annual growth rate (CAGR). This projected expansion during the forecast period can be associated with shifts in lifestyles and postponement of childbearing, integration of digital health, broadening of market accessibility, escalating rates of infertility, and individualized treatment plans. Noteworthy trends expected during the forecast period encompass tailored treatment methods, progress in the sphere of reproductive endocrinology, non-invasive methods of fertility monitoring, increased demand for assisted reproductive technologies, and the creation of innovative drug formulae.

You can Directly Purchase the Report Here:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13256

What Are the Key Market Innovations in theOvulation Inducing Drugs Market Over the Coming Years?

Leading firms in the ovulation-inducing drugs market are forging ahead with the development of novel drugs like Cetrorelix acetate, aimed at treating women in the process of controlled ovarian stimulation. Cetrorelix acetate for injection is a type of gonadotropin-releasing hormone antagonist that helps to inhibit premature ovulation in women undergoing in vitro fertilization. For example, in August 2022, Akorn Operating Company LLC, a pharmaceutical organization based in the US, was given the green light by the FDA for a generic version of cetrorelix acetate for injection, 0.25 mg. This represents the first AP-rated bioequivalent to the Merck Serono Cetrotide version that has been approved. Functioning as a GnRH antagonist, Cetrorelix acetate works by neutralizing the impact of the gonadotropin-releasing hormone. GnRH further prompts the release of luteinizing hormone and follicle-stimulating hormone from the pituitary gland. Additionally, it is employed in the prevention of premature LH spikes in women in the course of controlled ovarian stimulation, enhancing the chances of all eggs reaching maturity.

Who Are the Top Companies Driving Innovation and Growth in theOvulation Inducing Drugs Market?

Major companies operating in the ovulation inducing drugs market report are Pfizer Inc., Johnson And Johnson Pvt Ltd., Merck And Co. Inc., Abbvie Inc., Novartis AG, Bayer AG, Sanofi SA, Abbott Laboratories, Gilead Sciences Inc., Amgen Inc., Teva Pharmaceutical Industries Ltd., Janssen Pharmaceutical Inc., Mylan N.V, Astellas Pharma Inc., Sun Pharmaceuticals Industries Ltd., Aurobindo Pharma Limited, Dr Reddy’s Laboratories Ltd., Intas Pharmaceuticals Limited, Endo International Inc., Ferring Pharmaceuticals Inc., Lupin Limited, LIVZON Pharmaceutical Group Inc., Torrent Pharmaceuticals Ltd., Gedeon Richter PLC, Glenmark Pharmaceuticals Ltd., Fresenius Kabi AG, Zydus Pharmaceuticals (USA) Inc., Serum Institute of India Ltd., EMD Serono Inc., Cipla Inc.

Order Your Report Now For A Swift Delivery:

https://www.thebusinessresearchcompany.com/report/ovulation-inducing-drugs-global-market-report

Which Key Market Segments Comprise the Ovulation Inducing Drugs Market and Drive Its Revenue Growth?

The ovulation inducing drugs market covered in this report is segmented –

1) By Drug Class: Hormones, Therapeutics Drugs

2) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration

3) By End-User: Hospital, Homecare, Specialty Clinics, Other End-Users

Subsegments:

1) By Hormones: Gonadotropins, Clomiphene Citrate, Aromatase Inhibitors

2) By Therapeutic Drugs: Metformin, Letrozole, Bromocriptine

Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!

https://www.thebusinessresearchcompany.com/customise?id=13256&type=smp

Which Regions Are Emerging as Leaders in the Ovulation Inducing Drugs Market?

North America was the largest region in the ovulation-inducing drugs market in 2024. The regions covered in the ovulation inducing drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Browse Through More Reports Similar to the Global Ovulation Inducing Drugs Market 2025, By The Business Research Company:

Bridges, Gateways And Routers Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/bridges-gateways-and-routers-global-market-report

Drugs For Benign Prostatic hypertrophy Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/drugs-for-benign-prostatic-hypertrophy-global-market-report

Drugs For Hormonal Replacement Therapy Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/drugs-for-hormonal-replacement-therapy-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

What key factors are powering the surge in the ovulation inducing drugs market right now?

The ovulation-inducing drugs market has seen strong growth, projected to rise from $4.42 billion in 2024 to $4.74 billion in 2025, at a CAGR of 7.3%. Key historical growth drivers include the development of clomiphene citrate, the introduction of letrozole, regulatory approvals, and the emergence of ovulation predictor kits.

How fast Is the ovulation inducing drugs market expected to grow, and what’s its future value?

The ovulation-inducing drugs market is anticipated to see strong growth, reaching $6.12 billion in 2029 at a CAGR of 6.6%. Growth will be supported by changing lifestyles, delayed childbearing, digital health integration, expanding market reach, and increasing infertility rates. Key trends involve personalized treatment approaches, advancements in reproductive endocrinology, non-invasive fertility monitoring, rising demand for assisted reproductive technologies, and novel drug formulations.

Get your ovulation inducing drugs market report here!

https://www.thebusinessresearchcompany.com/report/ovulation-inducing-drugs-global-market-report

What are the leading drivers of growth in the ovulation inducing drugs market?

The rising focus on digital transformation is set to propel the output management software market. Digital transformation involves integrating digital technologies into business operations to enhance efficiency and customer service. The increasing adoption of digital transformation strategies is driven by technological advancements and evolving business needs. Output management software streamlines document workflows by integrating with digital systems, mobile devices, and online platforms, supporting digital transformation efforts. In June 2023, a report published by Skift in collaboration with Amazon Web Services revealed that over 80% of executives increased their digital transformation budgets compared to 2022, with approximately 31% reporting a budget increase of over 5% year-over-year. Thus, the growing emphasis on digital transformation is driving the expansion of the output management software market.

What are the key segments defining the ovulation inducing drugs market?

The ovulation inducing drugs market covered in this report is segmented –

1) By Drug Class: Hormones, Therapeutics Drugs

2) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration

3) By End-User: Hospital, Homecare, Specialty Clinics, Other End-Users

Subsegments:

1) By Hormones: Gonadotropins, Clomiphene Citrate, Aromatase Inhibitors

2) By Therapeutic Drugs: Metformin, Letrozole, Bromocriptine

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13256&type=smp

Who are the key players steering the development of the ovulation inducing drugs market?

Major companies operating in the ovulation inducing drugs market report are Pfizer Inc., Johnson And Johnson Pvt Ltd., Merck And Co. Inc., Abbvie Inc., Novartis AG, Bayer AG, Sanofi SA, Abbott Laboratories, Gilead Sciences Inc., Amgen Inc., Teva Pharmaceutical Industries Ltd., Janssen Pharmaceutical Inc., Mylan N.V, Astellas Pharma Inc., Sun Pharmaceuticals Industries Ltd., Aurobindo Pharma Limited, Dr Reddy’s Laboratories Ltd., Intas Pharmaceuticals Limited, Endo International Inc., Ferring Pharmaceuticals Inc., Lupin Limited, LIVZON Pharmaceutical Group Inc., Torrent Pharmaceuticals Ltd., Gedeon Richter PLC, Glenmark Pharmaceuticals Ltd., Fresenius Kabi AG, Zydus Pharmaceuticals (USA) Inc., Serum Institute of India Ltd., EMD Serono Inc., Cipla Inc.

What emerging trends are influencing the growth of the ovulation inducing drugs market?

Leading enterprises in the ovulation-inducing drugs market are working on innovative drugs like Cetrorelix acetate and securing permission to administer these drugs to women undertaking controlled ovarian stimulation. Cetrorelix acetate is an injectable gonadotropin-releasing hormone (GnRH) foe that prevents early ovulation in females undergoing in vitro fertilization (IVF). For example, in August 2022, Akorn Operating Company LLC, a pharmaceutical firm from the US, got FDA accreditation for a generic variant of the cetrorelix acetate injection, 0.25 mg (Cetrorelix). This is the first AP-rated bioequivalent to Merck Serono’s Cetrotide that has received permission. Cetrorelix acetate, being a GnRH antagonist, functions by obstructing the impacts of the gonadotropin-releasing hormone (GnRH). GnRH stimulates the pituitary gland to release luteinizing hormone (LH) and follicle-stimulating hormone (FSH). Furthermore, the drug helps avoid premature LH spikes in women who are undergoing controlled ovarian stimulation (COS) and ensures that all the eggs get an opportunity to develop.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13256

Which regions are most influential in expanding the ovulation inducing drugs market?

North America was the largest region in the ovulation-inducing drugs market in 2024. The regions covered in the ovulation inducing drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Browse Through More Similar Reports By The Business Research Company:

Bridges, Gateways And Routers Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/bridges-gateways-and-routers-global-market-report

Drugs For Benign Prostatic hypertrophy Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/drugs-for-benign-prostatic-hypertrophy-global-market-report

Drugs For Hormonal Replacement Therapy Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/drugs-for-hormonal-replacement-therapy-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

What Factors Are Driving the Anticipated Growth Rate of the Ovulation Inducing Drugs Market Through 2034?

The market for ovulation-inducing drugs has seen significant expansion recently. It is predicted to climb from $4.42 billion in 2024 to $4.74 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 7.3%. Factors influencing this growth during the past periods include the evolution of clomiphene citrate, the launch of letrozole, regularization and standardization, as well as the arrival of ovulation predictor kits.

The market for ovulation stimulating medications is predicted to experience robust growth in the coming years, reaching $6.12 billion by 2029 with a compound annual growth rate (CAGR) of 6.6%. The projected growth for this period can be traced back to several factors such as evolving lifestyle patterns and postponed parenthood, incorporation of digital health, broadening market penetration, increasing infertility rates, and tailored treatment protocols. Upcoming trends within this forecast period encompass customized treatment methods, advancements in the field of reproductive endocrinology, non-intrusive fertility tracking, a growing demand for assisted reproductive techniques, and the creation of innovative drug formulations.

What Industry-Specific Factors Are Fueling the Growth of the Ovulation Inducing Drugs Market?

An uptick in incidences of female infertility is predicted to bolster the progress of the ovulation-inducing drugs market. The term ‘female infertility’ pertains to a physiological state wherein a woman is unable to become pregnant or maintain a pregnancy to full term, despite regular unprotected sexual intercourse over a long time frame, generally one year or more. To address irregular or missng ovulation issues, ovulation-inducing medications are utilized to manage this form of infertility. These treatments interact with the hormonal pathways involved in ovulation, prompting the ovaries to expel matured eggs. For example, the US government agency, Centers for Disease Control and Prevention suggest that in 2022, there will be 6.1 million females aged between 15 and 44 in the US struggling with conception, accounting for 10% of all females. Furthermore, according to data from the US medical management firm, CCRM Management Company LLC, in June 2022, 1 in 4 couples worldwide typically face issues with infertility, increasing by 5% to 10% annually. As a result, the ovulation-inducing drug market is developing due to the growing prevalence of female infertility.

Ovulation Inducing Drugs Market Driver: Surge In Patients Choosing Ivf In The Ovulation Inducing Drugs Market

 

Request Your Free Ovulation Inducing Drugs Market Report Sample Now!

https://www.thebusinessresearchcompany.com/sample.aspx?id=13256&type=smp

Who Are the Major Industry Leaders Accelerating Growth in the Ovulation Inducing Drugs Market?

Major companies operating in the ovulation inducing drugs market report are Pfizer Inc., Johnson And Johnson Pvt Ltd., Merck And Co. Inc., Abbvie Inc., Novartis AG, Bayer AG, Sanofi SA, Abbott Laboratories, Gilead Sciences Inc., Amgen Inc., Teva Pharmaceutical Industries Ltd., Janssen Pharmaceutical Inc., Mylan N.V, Astellas Pharma Inc., Sun Pharmaceuticals Industries Ltd., Aurobindo Pharma Limited, Dr Reddy’s Laboratories Ltd., Intas Pharmaceuticals Limited, Endo International Inc., Ferring Pharmaceuticals Inc., Lupin Limited, LIVZON Pharmaceutical Group Inc., Torrent Pharmaceuticals Ltd., Gedeon Richter PLC, Glenmark Pharmaceuticals Ltd., Fresenius Kabi AG, Zydus Pharmaceuticals (USA) Inc., Serum Institute of India Ltd., EMD Serono Inc., Cipla Inc.

Which Current Trends Are Having the Most Impact on the Ovulation Inducing Drugs Market?

Leading enterprises in the ovulation-inducing drugs market are working on innovative drugs like Cetrorelix acetate and securing permission to administer these drugs to women undertaking controlled ovarian stimulation. Cetrorelix acetate is an injectable gonadotropin-releasing hormone (GnRH) foe that prevents early ovulation in females undergoing in vitro fertilization (IVF). For example, in August 2022, Akorn Operating Company LLC, a pharmaceutical firm from the US, got FDA accreditation for a generic variant of the cetrorelix acetate injection, 0.25 mg (Cetrorelix). This is the first AP-rated bioequivalent to Merck Serono’s Cetrotide that has received permission. Cetrorelix acetate, being a GnRH antagonist, functions by obstructing the impacts of the gonadotropin-releasing hormone (GnRH). GnRH stimulates the pituitary gland to release luteinizing hormone (LH) and follicle-stimulating hormone (FSH). Furthermore, the drug helps avoid premature LH spikes in women who are undergoing controlled ovarian stimulation (COS) and ensures that all the eggs get an opportunity to develop.

Pre-order Your Report for Quick and Easy Delivery!

https://www.thebusinessresearchcompany.com/report/ovulation-inducing-drugs-global-market-report

Which Market Segments Are Driving Strategic Growth and Trends in the Ovulation Inducing Drugs Market?

The ovulation inducing drugs market covered in this report is segmented –

1) By Drug Class: Hormones, Therapeutics Drugs

2) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration

3) By End-User: Hospital, Homecare, Specialty Clinics, Other End-Users

Subsegments:

1) By Hormones: Gonadotropins, Clomiphene Citrate, Aromatase Inhibitors

2) By Therapeutic Drugs: Metformin, Letrozole, Bromocriptine

Which Regions Are Key Players in the Growth of the Ovulation Inducing Drugs Market?

North America was the largest region in the ovulation-inducing drugs market in 2024. The regions covered in the ovulation inducing drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

How Is the Scope and Reach of the Ovulation Inducing Drugs Market Defined?

Ovulation-inducing drugs refer to medications that are used to stimulate the ovaries and promote the release of mature eggs (ovulation) in women who are experiencing difficulties with their menstrual cycles or are struggling with infertility. These drugs affect the hormonal balance in the body, specifically targeting the hormones involved in the ovulation process.

Browse Through More Similar Reports By The Business Research Company:

Bridges, Gateways And Routers Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/bridges-gateways-and-routers-global-market-report

Drugs For Benign Prostatic hypertrophy Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/drugs-for-benign-prostatic-hypertrophy-global-market-report

Drugs For Hormonal Replacement Therapy Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/drugs-for-hormonal-replacement-therapy-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: